Loperamide
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Loperamide: From Diarrhoea to Acute Contagious Conjunctivitis
One-Sentence Summary
Loperamide is a peripherally-acting μ-opioid receptor agonist internationally used to control diarrhoea. The TxGNN model predicts it may be effective for Acute Contagious Conjunctivitis, but this prediction is currently supported by 0 clinical trials and 0 publications, and the model’s own rationale flags it as a likely spurious (false-positive) association rather than a plausible mechanistic link.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Diarrhoea (internationally recognised use; not SAHPRA-registered — see Market Status below) |
| Predicted New Indication | Acute Contagious Conjunctivitis |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L5 (model prediction only, no supporting trials/literature) |
| South Africa Market Status | Not marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the current evidence pack. Based on known pharmacology, loperamide is a peripherally-acting μ-opioid receptor agonist that acts on the myenteric plexus of the gut to slow intestinal motility; it does not cross the blood-brain barrier and has no ocular formulation.
The model’s own repurposing rationale explicitly cautions against this prediction: it states there is no known pharmacological connection between loperamide’s peripheral antidiarrheal mechanism and acute contagious conjunctivitis (a viral/bacterial or allergic ocular condition), and that the high TxGNN score is most likely explained by node-proximity artefacts in the knowledge graph rather than a genuine biological relationship.
This pattern repeats across all ten of the model’s top predictions for this drug — nine of the ten relate to conjunctivitis-family conditions with no cited mechanistic basis, and the second-ranked prediction (amebic dysentery) is flagged as a potential safety risk rather than a therapeutic opportunity: international guidance treats loperamide as relatively contraindicated in invasive/inflammatory dysentery because slowing gut motility can delay pathogen/toxin clearance and increase the risk of toxic megacolon. None of the ten candidates in this evidence pack should be read as a credible repurposing signal without independent mechanistic or clinical corroboration.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
Loperamide is currently not marketed in South Africa according to this evidence pack (0 SAHPRA registrations on record).
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Note: this evidence pack flags TFDA/SAHPRA warning and contraindication data as a Blocking data gap — no safety pre-screening (S1) has been possible for this candidate.
Conclusion and Next Steps
Decision: Hold
Rationale: All ten predicted indications sit at Evidence Level L5 (model prediction only) with zero supporting clinical trials or literature, and the model’s own rationale text identifies the top-ranked prediction — along with most of the others — as a likely knowledge-graph artefact rather than a mechanistically plausible signal. One candidate (amebic dysentery) may represent an actual safety risk rather than a therapeutic use. There is no basis to advance any of these candidates at this time.
To proceed, the following is needed:
- TFDA/SAHPRA-approved Professional Information (warnings, contraindications) — currently a Blocking gap
- Confirmed mechanism of action data from DrugBank or equivalent source
- Independent literature or preclinical evidence establishing a plausible mechanistic link before any candidate in this set is escalated beyond S0
- If South African market entry is ever considered, a full SAHPRA registration pathway assessment, since loperamide currently has no registered product in this market
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.